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Introduction
Over the last 10 years, complementary and alternative (CAM)
therapies have grown into a multibillion dollar industry in the
United States (1–4). In particular, the use of botanical dietary
supplements (BDS) has surged, with more than 60 million
Americans now using herbal or other supplements, and spending
over $600 million annually on botanical products alone (5).
This new era of popularity with BDS in the United States is
accompanied by questions regarding the quality, consistency
and safety of commercially available herbal products. Among
the uncertainties associated with the use of BDS are variability
in label information (6) and product composition (7).
With the rise in the simultaneous use of both herbal and con-
ventional modalities (8), health care providers, in particular,
have a vital stake in knowing what their clients are consuming
and in assessing the quality of these products. Such data would
contribute to the safe use of herbs by ensuring consistency of
dose of herbal actives. Health care providers who are currently
hesitant to recommend or discuss BDS use with their patients
(9–12) would likely be less reticent if they were confident
about the product quality.
Recently, Garrard et al. (6) found wide-ranging label differ-
ences in the stated ingredients and recommended daily serving
sizes across multiple brands for ten different herbs. However,
this study did not attempt to correlate label claims with the
actual contents. As a result, the question regarding the accuracy
in the stated composition of the products remained unan-
swered. To date, few comparative analyses of the quality of
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The growing popularity of botanical dietary supplements (BDS) has been accompanied by concerns
regarding the quality of commercial products. Health care providers, in particular, have an interest in know-
ing about product quality, in view of the issues related to herb-drug interactions and potential side effects.
This study assessed whether commercial formulations of saw palmetto, kava kava, echinacea, ginseng and
St. John’s wort had consistent labeling and whether quantities of marker compounds agreed with the
amounts stated on the label. We purchased six bottles each of two lots of supplements from nine manu-
facturers and analyzed the contents using established commercial methodologies at an independent labo-
ratory. Product labels were found to vary in the information provided, such as serving recommendations
and information about the herb itself (species, part of the plant, marker compound, etc.) With regard to
marker compound content, little variability was observed between different lots of the same brand, while
the content did vary widely between brands (e.g. total phenolic compounds in Echinacea ranged from
3.9–15.3 mg per serving; total ginsenosides in ginseng ranged from 5.3–18.2 mg per serving). Further, the
amounts recommended for daily use also differed between brands, increasing the potential range of a con-
sumer’s daily dose. Echinacea and ginseng were the most variable, while St. John’s wort and saw palmetto
were the least variable. This study highlights some of the key issues in the botanical supplement market,
including the importance of standardized manufacturing practices and reliable labeling information. In
addition, health care providers should keep themselves informed regarding product quality in order to be
able to appropriately advise patients utilizing both conventional and herbal medicines.
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marketed herbal products exist, and of these, most come from
large consumer organizations (13–14), not independent aca-
demic institutions (15). At our Center, we have previously
tested nine brands of Chinese Red Yeast Rice, and it was found
that these products varied greatly in their content of monacolin
K and total monacolins (16). In the literature, studies on
St. John’s wort describe wide variability in marker compound
content among the different commercial brands (17–19). An
investigation of commercial ginseng products also found
variability in the concentration of marker compounds,
although the data did suggest that at least the US ginseng
products are correctly labeled as to the plant genus (20). Other
studies involving feverfew (21), garlic (22) and other herbs
(23) also suggest inconsistencies among products with regard
to the content of marker compounds.
In the current study, we examined five of the top selling (2)
herbs in the United States—St. John’s wort, ginseng, saw
palmetto, kava kava and echinacea. The aim was to evaluate the
quality and consistency of the available commercial products and
to use this information to inform practitioners regarding the use
of BDS. After documenting the label information, we analyzed
the products for the presence or absence of toxic metal contam-
inants and for the presence and quantity of marker compound.
Materials and Methods
In order to sample the products most likely to be available to the
average consumer, we purchased the products from nine manu-
facturers, found at chain pharmacies and retail stores, and
through internet and mail order. All the products were nationally
distributed at the time of the study and were chosen based upon
their availability at the targeted outlets at the time of purchase. A
total of twelve bottles of each herb (six bottles each of two dif-
ferent lot numbers) were purchased from all the identified man-
ufacturers for which the herb was available. Phytochemical
analysis was performed at an independent laboratory (Alpha
Chemical and Biomedical Laboratories, Inc., Petaluma, CA) in
order to replicate the resources available to commercial providers.
The methodologies followed were those commonly used at the
time of conducting this study, i.e., in late 1999. All samples were
tested prior to the expiration dates listed on the bottles.
Label Analysis
For each supplement, information obtained from the labels and
packaging were analyzed for the plant species, part of the plant
utilized, method of preparation (e.g. dried herb, extract, etc.),
type of marker compound, claimed amounts of marker com-
pound and suggested daily serving size. Where necessary, the
quality control departments of the companies were contacted
in order to augment the information not available on the label.
Content Analysis
Once label information was recorded, unopened bottles were
sent to the independent laboratory for analysis. Three pills from
each bottle were analyzed and reported as pooled results. For
each herb, a marker compound was identified and quantified by
high-performance liquid chromatography (HPLC) in all the
herbs except for saw palmetto, in which free fatty acids were
measured by gas chromatography. Sigma reference standards
were used in the content analysis.
Echinacea
The echinacea products were analyzed by HPLC, and the
marker compounds were reported as total phenolic com-
pounds, including echinacoside, cattaric acid, chlorogenic acid
and cichoric acid. Samples were prepared by heating 0.1 g of
ground plant material or extract in a 40 ml vial with 20.0 ml of
methanol for 15 min, sonicating and adding an additional 20
ml of water. Samples were filtered prior to HPLC analysis.
Saw Palmetto
Saw palmetto was analyzed for free fatty acids using gas chro-
matography with flame ionization detection (GC-FID). This
procedure utilized derivatization of free fatty acids with
BSTFA (99%):TMCS (1%) reagent. This reagent does not
hydrolyze or transesterify fatty acids present as methyl, ethyl
esters, triglycerides or wax esters that may be added to the
formulations of saw palmetto.
Ginseng
Ginseng was analyzed by HPLC for seven of these compounds
and reported as total ginsenosides. The ginsenosides were
separated by reverse phase liquid chromatography on a C-18
column and detected with UV at 210 nm. Quantification was
carried out by the comparison of peak areas from the sample
with those of the reference standards.
St. John’s Wort
St. John’s wort was measured for hypericin by HPLC analysis.
Samples were prepared with a 90:10 MeOH:DMSO solvent
and filtered through a 45-nm PTFE syringe filter. This sample
was compared with hypericin standard and detected with UV
at 590 nm.
Kava Kava
Kava Kava was analyzed by HPLC and reported as total kavalac-
tones, including methysticin, dihydromethysticin, kawain, dihy-
drokawain, yangonin and desmethoxyyangonin. An appropriate
standard of d,1-Kawain was prepared with methanol and
detection was performed at UV 220 nm.
Heavy Metals
Heavy metals (lead, arsenic, cadmium and mercury) were ana-
lyzed by X-ray spectrophotometry and reported as percentages
(by weight) in the test substance.
Data Analysis
Results for both lot numbers for each of the herbs were pooled
and reported as average amounts of marker compound measured.
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For the products that made label claims of marker content,
measured amounts were also reported as a percentage of the
claimed amounts. Suggested daily serving sizes were calcu-
lated by multiplying the claimed amount of marker compound
(where available) with the recommended intake per day.
Actual daily serving sizes were calculated by multiplying the
measured amounts of the marker compound with the recom-
mended daily intake, assuming that consumers would correctly
follow the instructions on the label. Suggested and actual daily
serving sizes were then compared. Cases in which the product
labels recommended a range of serving size (e.g. 1–3 caps),
the results were reported as a range.
Results
Products Obtained for Analysis
For the products that were purchased over-the-counter, six
bottles each of identical preparations from two different lots
were obtained. For the supplements purchased via mail order,
we were able to obtain six bottles each from two different lots;
however, the preparations were not always consistent between
lots. For example, in one instance, a supplier sent six bottles of
one lot containing aerial parts of Echinacea purpurea and six
bottles of another lot containing root of Echinacea purpurea
and angustifolia. The same supplier sent six bottles of ginseng
extract and six bottles of ginseng root.
Label Information
Product labels were found to vary in the information provided.
In most cases, the manufacturers’ quality control personnel
were contacted and requested to verify the plant species, plant
part and extraction procedure for the particular supplement by
providing them with the lot numbers utilized in the study. Most
manufacturers were able to provide the requested information,
but some were not. Certain quality control personnel were
difficult to contact; one was unable to locate records (they no
longer manufactured the product at the time of contact) and
another stated ‘legal concerns’ of providing this information
over the phone. By and large, however, most manufacturers
were very willing to be helpful in providing this information.
Overall Analysis
When the amount of marker compound was analyzed for indi-
vidual samples within the same lot of a given brand, the content
did not vary substantially. However, the measured amounts
often varied from the stated amounts on the label, and some
brands made no claims regarding the marker compound content
at all for certain supplements. In general, variation between
different lots of the same brand was relatively less than the
variation between brands (Fig. 1). For certain herbs (saw
palmetto, St. John’s wort and kava kava), the plant species,
part of the plant utilized and the type of preparation were
consistent across brands, whereas other herbs (echinacea and
ginseng) were more variable. All the products contained the
marker compounds appropriate to the herb tested for, suggesting
eCAM 2004;1(3) 307
at the very least that the products contained the correct herb.
Finally, amounts of heavy metals, where detected, were below
acceptable standards, in accordance with the California
Proposition 65 (24).
Echinacea
For echinacea (Table 1), a total of ten different preparations
were tested since brand ‘b’ sent two different preparations. Six
of the ten preparations utilized Echinacea purpurea, one used
purpurea and angustifolia, one used angustifolia and/or
pallida and the species for two preparations were unavailable.
Four of the ten products used both aerial parts and root, two
used just aerial parts, two used just root and information on the
remaining two products was unavailable.
Of all the samples tested, the echinacea (and ginseng; see
below) products were the most variable. For those echinacea
products that stated the amounts of the marker compound, two
out of six (33%) were within  10% of their claim. Four of the
ten echinacea preparations made no claims regarding the
amount of marker compound at all, and the type of marker
compound itself was unavailable in six of the ten preparations.
Among the others, no consistency was observed in the stated
marker compound, whether it was echinacosides, phenolics or
acylamides. Measured amounts of the marker compound for
echinacea ranged from 78–173% of the stated amounts.
Calculations for the actual daily dose of echinacea ranged
between 7 and 137.7 mg of echinacosides.
Ginseng
For ginseng (Table 2), a total of nine preparations were tested
since one brand (‘e’) was unavailable, and one brand (‘b’) sent
one lot of root and one lot of extract via mail order. Measured
amounts ranged from 44–261% of the stated amounts. For
those products that stated the amounts of the marker compound,
one out of seven (14%) were within  10% of their claim.
Calculations for the actual daily dose of total ginsenosides
ranged from 10.6–72.8 mg among the brands.
St. John’s Wort
For St. John’s wort (Table 3), ten products were tested. One
product (‘i’) was unavailable and two products (‘e’ and ‘f’) sent
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Figure 1. Comparison of Variability of Saw Palmetto Formulations Between
Different Lots of the Same Brand and Between Brands.
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Table 1. Echinacea formulations
Manufacturer Species Plant part Preparation Standardization Stated amount Measured amount Percent of Suggested Total daily dose 
of marker (mg) marker (mg) (average label claim servings of marker compound
of two lots) per day (mg)
a Echinacea Herb and root Extract TLC1 and FTIR2 — 5.7  2.0 — 6 34.2
purpurea
b (1)* Echinacea Herb Powder N/A 10 15.3  0.4 153  4% 3–9 45.9–137.7
purpurea
b (2)* Echinacea Herb and root Powder with Echinacoside — 9.6  0.7 — 2 19.2
purpurea and extract
Echinacea 
angustifolia
c N/A N/A N/A N/A 10 13.9  0.2 139  2% 1–4 13.85–55.4
d Echinacea Whole plant Extract 4% phenolics 5 5.4  0.2 107  5% 2 10.8
purpurea and root
e Echinacea Aerial Powder N/A — 12.6  0.2 — 6–9 75.6–113.4
purpurea
f Echinacea Root Extract Acylamides — 3.5  0.4 — 2 7
purpurea 0.3%
g Echinacea Whole plant Extract 4% phenolics 5 5.2  0.7 104  14% 2 10.4
purpurea and root
h N/A N/A N/A N/A 3 5.2  0.2 173  7% 2 10.4
i Echinacea Root Powder N/A 5 3.9  0.3 78  7% 2 7.8
angustifolia
and/or pallida
1Thin Layer Chromatography.
2Fourier Transform Infrared Spectroscopy.
*Reported as two separate products since different preparations were sent; N/A  information not available.
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Table 2. Saw palmetto formulations
Manufacturer Species Plant part Preparation Standardization Stated amount Measured amount Percent of Suggested Total daily dose 
of marker (mg) marker (mg) (average label claim servings of marker compound
of two lots) per day (mg)
a Serenoa repens Fruit Extract Match ‘standard’ — 45.1  0.9 — 6 270.6
b Serenoa serrulata Fruit Extract 75–85% fatty acids — 75.0  1.4 — 2 150
c N/A N/A N/A N/A — 52.4  2.3 — 2–4 104.8–209.6
d Serenoa repens Fruit Extract 80% fatty acids 128 103.8  8.2 81  6% 2 207.6
e Serenoa repens Fruit Extract 45% sterols 36 27.8  2.5 77  7% 4 111.2
f Serenoa repens Fruit Extract Total free fatty acids 35–45% 136–152# 133.2  1.4 93  1% 2 266.4
g Serenoa repens Fruit Extract 80% fatty acids 64 68.1  2.4 106  4% 4 272.4
h N/A N/A N/A N/A 128 101.6  0.7 79  1% 2 203.2
*Reported as two separate products since lots were different preparations; #use 144 for comparison; N/A  information not available.
Table 3. Ginseng formulations
Manufacturer Species Plant part Preparation Standardization Stated amount Measured amount Percent of Suggested Total daily dose 
of marker (mg) marker (mg) (average label claim servings of marker compound
of two lots) per day (mg)
a Panax ginseng Root Powder 12 mg ginsenosides 12 5.3  0.2 44  2% 2 10.6
b (lot 1)* Panax ginseng Root N/A N/A 8.0 9.0  1.5 112  19% 4 36.0
b (lot 2)* Panax ginseng Root Softgel 7% ginsenosides 10.0 17.5  0.13 175  1% 2 35.0
c N/A N/A N/A N/A 7.0 18.2  0.4 261  6% 1–4 18.2–72.8
d Panax ginseng Root Extract 7% (7 mg) ginsenosides 7.0 7.4  0.6 106  8% 3 22.2
f Panax ginseng Root Extract 5% ginsenosides 5.0 7.3  1.0 — 2 14.6
g Panax ginseng Root Extract 7% (7 mg) ginsenosides 7.0 8.2  0.3 117  4% 3 24.6
h N/A N/A N/A N/A 7.0 8.0  0.5 114  6% 2 16.0
i N/A N/A N/A N/A - 11.1  1.4 — 2 22.2
*Reported as two separate products since lots were different preparations; N/A  information not available.
two different preparations. Measured amounts of hypericin
were mostly consistent among brands, ranging from 88–110%
of the stated amounts. One outlier contained 139% of the stated
amount. All the ten products stated the amounts of marker
compound, and eight of these (80%) were within  10% of
their claim. Stated amounts of the marker compound were
either 0.45 mg or 0.9 mg per capsule, and all the brands used
the same type of preparation. Calculations for the actual daily
doses ranged from 0.9–3.56 mg hypericin per day.
Saw Palmetto
Eight saw palmetto products (Table 4) were tested. Product ‘i’
was unavailable. Marker compounds ranged from 77–106% of
the stated amounts. Three of the eight preparations made no
claims regarding the marker compounds. Of the remaining
five, two (40%) were within  10% of their claim. Calculations
of the actual daily doses ranged from 111.2–272.4 mg/day
among the brands investigated.
Kava Kava
Eight kava products (Table 5) were tested. Products ‘h’ and ‘i’
were unavailable and product ‘b’ sent two different prepara-
tions. Total kavalactones ranged from 42–133% of the stated
amounts. The stated amounts ranged from 10–70 mg of
kavalactones per tablet, and one of the eight preparations made
no claim regarding the marker compound. Of the remaining
seven, five (71%) were within  10% of their claim. Actual
calculated daily doses were between 41.7 and 220 mg of
kavalactones among the commercial brands.
Discussion
Consistent with previous studies (6), the current study found
that product labels of BDS vary in the information provided.
Particularly, for echinacea and ginseng, the labels often varied
with regard to the plant species, part of the plant utilized, type
of preparation, type of marker compound, standardization of
marker compound, claimed amounts of marker compound and
the recommended serving size. While the content tended not to
vary either within the same lot or across different lots of a
given brand, considerable differences between stated and
actual amounts of marker compound were found in most
brands. In addition, large differences were observed in the
marker compound content among brands. This problem,
coupled with the inconsistency in the recommended serving
sizes, led to even greater variability in the potential daily
ingestion of presumed active constituents.
St. John’s wort and saw palmetto were the two herbs with the
least variability among brands for the stated and measured
amounts of marker compound as well as for the recommended
serving sizes. It is notable that three major systematic reviews
exist for both saw palmetto (25–27) and St. John’s wort (28–30)
and that standardized and consistent products have been used in
these clinical trials. This consistency appears to be reflected in
the relative uniformity of the commercially available products
310 Phytochemical Assays of Commercial BDS
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for these herbs. Although there are existing reviews for both
echinacea and ginseng, there was no similar consensus in the
clinical trials, and the products utilized varied for plant species,
part of the plant and the type of preparation (31,32). Given this
difference, it is perhaps not surprising that the echinacea and
ginseng reviews tend to report mixed results, whereas for saw
palmetto and St. John’s wort, results are generally positive. The
prevalence of standardized formulations of St. John’s wort and
saw palmetto in randomized controlled trials therefore suggests
a relationship between the quality of commercial products and
the quality of evidence-based research on these products. It
would follow that improvement in the scientific database on
herbal efficacy and safety would be facilitated by improving the
product quality and consistency.
A fundamental limitation of this study, and the state of the
art in the science of botanical medicine in general, is that
botanical marker compounds are not necessarily the biologi-
cally active ingredients (33). Even in the case of St. John’s
wort, for which the marker compound—hypericin—is well
characterized, it is possible that another component—hyper-
forin—may be more active (34–36). Therefore, currently, the
purpose of marker compounds is limited to their action as
surrogates to ensure the reproducibility and quality of the
preparatory process. While this study does highlight the incon-
sistencies among the products, they may not necessarily correlate
with differences in the clinical activity.
In addition, consensus in the dietary supplement industry on
the methodology for quantifying phytochemical markers is not
complete. Therefore, our study used commonly accepted
methods in commercial use available at that time. Presumably,
the state of the art has advanced since this time, and it is pos-
sible that the products would be better characterized and vali-
dated with evolving methodologies. In addition, since the time
of the study, the FDA has proposed new labeling requirements
(37,38) as well as manufacturing standards (38) (current good
manufacturing practices—CGMPs) in order to ensure that
BDS are manufactured consistently to ‘identify purity, quality,
strength and composition’. Therefore, as new methodological
techniques are developed and published, some of the problems
uncovered by this study will be eliminated. In addition, if the
new FDA rules for CGMPs are approved and implemented,
further quality improvements are likely to follow. Future inves-
tigations could assess the effect of evolving scientific and
regulatory standards on improving product quality.
Given the growing concern regarding the potential for herb-
drug interactions (39) as well as the adverse effects reported
with some herbs (40), the current study does have implications
for clinical practice. We suggest that when physicians deter-
mine that their patients are using BDS, they should ask them to
bring in the bottles, along with their regular medicines. Health
care providers can help their patients make informed purchas-
ing choices, advising them to choose products most likely to be
of high quality. While this study highlights the fact that label
information may not always be complete or reliable, one should
at least get into the habit of looking for the presence of the
following: documentation of the exact amount of markerTa
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compound, botanical name of the herb, recommended serving
size in milligrams, batch or lot number, expiration date and the
name/address of the manufacturer. Finally, the presence of a
Dietary Supplement Verification Certificate from the US
Pharmacopeia, or other related groups, indicates a manufac-
turer’s compliance with a quality validation program (41).
Once a product is chosen, it is important to note that switching
brands during a course of treatment may affect the amount of
presumed active constituents and therefore, the efficacy and
safety. Given the brand-to-brand variability highlighted by this
study, once a patient achieves a desired outcome with a BDS,
it is inadvisable to change the serving size or brand. Following
is a summary of the recommendations to health care providers
discussing herbal supplement use with their patients.
Recommendations to Physicians Guiding Patients in
Herbal Supplement Use
1. Ask your patients about herb use.
2. Ask patients to bring the bottles of the supplement with
them during clinic visit.
3. Where possible, select products used in randomized,
controlled trials.
4. Review efficacy/safety data with established resources
(e.g. National Library of Medicine).
5. Recognize that switching brands may alter efficacy or side
effects.
6. Note potential side effects or changes in efficacy in a chart.
7. If change in efficacy is reported, assess BDS label for
change in source material.
8. When possible, check available resources on quality
(e.g. ConsumerLab).
In the near future, the development of a more sophisticated
knowledge base for botanical supplements will be accompanied
by a rising demand for standardized manufacturing practices and
quality control methods, reliable labeling information and
knowledgeable health care providers able to advise patients
utilizing both conventional and herbal modalities. It is critical
that industry, government and academia work together to achieve
further progress in assuring consumer access to high quality, safe
dietary supplements. Such trends will further enable safe clinical
practice and the testing of botanical supplements to proceed with
confidence, thus contributing to the growing evidence base
regarding their function and leading to more reliable commercial
products with well-characterized safety and efficacy profiles.
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